Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

被引：1
|
作者：
Tanvetyanon, T [1 ]
机构：
[1] Loyola Univ, Stritch Sch Med, Cardinal Bernardin Canc Inst, Maywood, IL 60153 USA
来源：
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2005年 / 97卷 / 01期
关键词：
D O I：
10.1093/jnci/dji016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [1] Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    Grenader, T
    Shavit, L
    Uziely, B
    Peretz, T
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (03) : 235 - 236
  • [2] Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    Parker, CC
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (19) : 1480 - 1480
  • [3] Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    Saad, F
    Gleason, DM
    Murray, R
    Tchekmedyian, S
    Venner, P
    Lacombe, L
    Chin, JL
    Vinholes, JJ
    Goas, JA
    Zheng, M
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11) : 879 - 882
  • [4] Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer - Response
    Saad, F
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01) : 70 - 71
  • [5] Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer - Response
    Saad, F
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (19): : 1480 - 1481
  • [6] Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer
    Vordos, D
    Paule, B
    Vacherot, F
    Allory, Y
    Salomon, L
    Hoznek, A
    Yiou, R
    Chopin, D
    Abbou, CC
    de la Taille, A
    BJU INTERNATIONAL, 2004, 94 (04) : 524 - 527
  • [7] Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer
    Smith, Matthew R.
    Cook, Richard J.
    Coleman, Robert
    Brown, Janet
    Lipton, Allan
    Major, Pierre
    Hei, Yong Jiang
    Saad, Fred
    UROLOGY, 2007, 70 (02) : 315 - 319
  • [8] Zoledronic acid significantly reduces fractures in patients with hormone-refractory prostate cancer metastatic to bone
    Fred, S
    Gleason, D
    Murray, R
    Venner, P
    Tchekmediyian, S
    Chin, J
    Goas, A
    Reitsma, D
    Seaman, J
    JOURNAL OF UROLOGY, 2002, 167 (04): : 175 - 175
  • [9] Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease
    Berruti, A
    Tucci, M
    Mosca, A
    Tarabuzzi, R
    Gorzegno, G
    Terrone, C
    Vana, F
    Lamanna, G
    Tampellini, M
    Porpiglia, F
    Angeli, A
    Scarpa, RM
    Dogliotti, L
    BRITISH JOURNAL OF CANCER, 2005, 93 (06) : 633 - 638
  • [10] Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease
    A Berruti
    M Tucci
    A Mosca
    R Tarabuzzi
    G Gorzegno
    C Terrone
    F Vana
    G Lamanna
    M Tampellini
    F Porpiglia
    A Angeli
    R M Scarpa
    L Dogliotti
    British Journal of Cancer, 2005, 93 : 633 - 638
12345